皮质类固醇在心脏骤停中的疗效与安全性:随机对照试验的系统评价、Meta分析与试验序贯分析
该系统评价与Meta分析纳入8项随机对照试验共2213例院内外心脏骤停患者,评估皮质类固醇对比安慰剂或常规治疗的疗效与安全性。主要结果显示,皮质类固醇对最长随访点死亡率影响不确定(RR 0.96,95%CI 0.90-1.02,极低确定性,试验序贯分析未达到所需信息量);可能提高自主循环恢复(ROSC)(RR 1.32,95%CI 1.18-1.47,中等确定性);可能增加出院时神经功能良好存活的可能性(RR 1.49,95%CI 0.87-2.54,低确定性)。安全性方面,可能降低呼吸机相关性肺炎风险(RR 0.76,95%CI 0.46-1.09,低确定性),可能增加肾功能衰竭(RR 1.29,95%CI 0.84-1.99,低确定性),对出血(RR 2.04,95%CI 0.53-7.84,极低确定性)和腹膜炎(RR 10.54,95%CI 2.99-37.19,极低确定性)影响不确定。作者结论认为合并证据稀疏且不精确导致低或极低确定性。
要点
- 8项RCT共2213例心脏骤停患者,皮质类固醇对最长随访点死亡率影响不确定(RR 0.96,95%CI 0.90-1.02,极低确定性,试验序贯分析未达所需信息量)。
- 皮质类固醇可能提高自主循环恢复(ROSC)(RR 1.32,95%CI 1.18-1.47,中等确定性)。
- 可能增加出院时神经功能良好存活的可能性(RR 1.49,95%CI 0.87-2.54,低确定性)。
- 可能降低呼吸机相关性肺炎风险(RR 0.76,95%CI 0.46-1.09,低确定性),可能增加肾功能衰竭(RR 1.29,95%CI 0.84-1.99,低确定性)。
- 对出血(RR 2.04,95%CI 0.53-7.84,极低确定性)和腹膜炎(RR 10.54,95%CI 2.99-37.19,极低确定性)影响不确定。
适用人群与场景
- 院内外心脏骤停后患者(纳入的8项RCT共2213例)。
研究设计与关键结果
- 研究类型:随机对照试验的系统评价、Meta分析与试验序贯分析;纳入8项RCT,共2213例患者。
- 干预与对照:皮质类固醇对比安慰剂或常规治疗。
- 主要终点:最长随访点死亡率,皮质类固醇影响不确定(RR 0.96,95%CI 0.90-1.02,极低确定性,试验序贯分析未达到所需信息量)。
- 自主循环恢复(ROSC):皮质类固醇可能提高ROSC(RR 1.32,95%CI 1.18-1.47,中等确定性)。
- 出院时神经功能良好存活:可能增加其可能性(RR 1.49,95%CI 0.87-2.54,低确定性)。
- 呼吸机相关性肺炎:可能降低风险(RR 0.76,95%CI 0.46-1.09,低确定性)。
- 肾功能衰竭:可能增加风险(RR 1.29,95%CI 0.84-1.99,低确定性)。
- 出血:影响不确定(RR 2.04,95%CI 0.53-7.84,极低确定性);腹膜炎:影响不确定(RR 10.54,95%CI 2.99-37.19,极低确定性)。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析;采用GRADE方法评级证据确定性。
- 死亡率:极低确定性;ROSC:中等确定性;神经功能良好存活:低确定性;呼吸机相关性肺炎:低确定性;肾功能衰竭:低确定性;出血:极低确定性;腹膜炎:极低确定性。
- 局限:作者指出合并证据稀疏且不精确,导致低或极低确定性证据;试验序贯分析显示死亡率所需信息量未达到。
对床旁实践的改变
- 作者结论认为,在心脏骤停期间或之后,皮质类固醇对死亡率影响不确定,但可能提高ROSC,并可能增加出院时神经功能良好存活的可能性;可能降低呼吸机相关性肺炎、可能增加肾功能衰竭,对出血和腹膜炎影响不确定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Post-cardiac arrest, outcomes for most patients are poor, regardless of setting. Many patients who do achieve spontaneous return of circulation require vasopressor therapy to maintain organ perfusion. There is some evidence to support the use of corticosteroids in cardiac arrest.
RESEARCH QUESTION: Assess the efficacy and safety of corticosteroids in patients following in- and out-of-hospital cardiac arrest.
STUDY DESIGN AND METHODS: We searched databases CINAHL, EMBASE, LILACS, MEDLINE, Web of Science, CENTRAL, ClinicalTrails.gov, and ICTRP. We included randomized controlled trials (RCTs) that examined the efficacy and safety of corticosteroids, as compared to placebo or usual care in patients post-cardiac arrest. We pooled estimates of effect size using random effects meta-analysis and report relative risk (RR) with 95% confidence intervals (CIs). We assessed risk of bias (ROB) for the included trials using the modified Cochrane ROB tool and rated the certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation methodology.
RESULTS: We included 8 RCTs (n = 2213 patients). Corticosteroids administered post-cardiac arrest had an uncertain effect on mortality measured at the longest point of follow-up (RR 0.96, 95% CI 0.90-1.02, very low certainty, required information size not met using trial sequential analysis). Corticosteroids probably increase return of spontaneous circulation (ROSC) (RR 1.32, 95% CI 1.18-1.47, moderate certainty) and may increase the likelihood of survival with good functional outcome (RR 1.49, 95% CI 0.87-2.54, low certainty). Corticosteroids may decrease the risk of ventilator associated pneumonia (RR 0.76, 95% CI 0.46-1.09, low certainty), may increase renal failure (RR 1.29, 95% CI 0.84-1.99, low certainty), and have an uncertain effect on bleeding (RR 2.04, 95% CI 0.53-7.84, very low certainty) and peritonitis (RR 10.54, 95% CI 2.99-37.19, very low certainty).
CONCLUSIONS: In patients during or after cardiac arrest, corticosteroids have an uncertain effect on mortality but probably increase ROSC and may increase the likelihood of survival with good functional outcome at hospital discharge. Corticosteroids may decrease ventilator associated pneumonia, may increase renal failure, and have an uncertain effect on bleeding and peritonitis. However, the pooled evidence examining these outcomes was sparse and imprecision contributed to low or very low certainty of evidence.
参考来源
- Penn J, Douglas W, Curran J, et al. Efficacy and safety of corticosteroids in cardiac arrest: a systematic review, meta-analysis and trial sequential analysis of randomized control trials. Crit Care. 2023. PMID: 36631807. doi:10.1186/s13054-022-04297-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。